Bevacizumab plus chemotherapy for patients with advanced pulmonary adenocarcinoma harboring EGFR mutations

PURPOSE: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) and bevacizumab plus chemotherapy were effective for EGFR-mutant patients. However, the appropriated treatment orders remained controvertible. We investigated the efficacy of treatment orders between bevacizumab plus...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, R.-L., Chen, H.-J., Jiang, B.-Y., Zhang, X.-C., Zhou, Q., Tu, H.-Y., Zhong, W.-Z., Wu, Y.-L., Yang, J.-J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5797192/
https://www.ncbi.nlm.nih.gov/pubmed/28702789
http://dx.doi.org/10.1007/s12094-017-1714-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5797192/
https://www.ncbi.nlm.nih.gov/pubmed/28702789
http://dx.doi.org/10.1007/s12094-017-1714-2

Ejemplares similares